AI-generated summary
The authors report early observations in seven Parkinson's disease patients who used daily transcranial red and near-infrared light therapy for six to thirty-four months. They describe apparent improvements in several non-motor symptoms, such as fatigue, sleep, and mood, assessed by patients, spouses and clinicians. The abstract notes the treatment was well tolerated.
- Participants
- 7
- Who or what was studied
- Seven people with Parkinson's disease who used daily transcranial red and near-infrared photobiomodulation at home.
- Wavelengths
- 630, 850, 670, 810, 660 nm
- Limits stated in the abstract
- The study is a small observational report of seven patients with no control group, and assessments were based largely on subjective reports.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 630 nm, 850 nm, 670 nm, 810 nm, 660nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Light-emitting diode, Anxiety. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.